^
Association details:
| Biomarker: | EGFR exon 19 deletion + TP53 exon 8 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma
Published date:
11/02/2021
Excerpt:
We present a 62-year-old man with progressive vomiting, headache, short-term memory impairment, and left lower limb hyposthenia….Bone needle biopsy documented TTF1+ lung adenocarcinoma….Next-generation sequencing reported deletion of exon 19 of EGFR and mutation 8 of TP53. Osimertinib 80 mg was promptly started and WBRT interrupted....Radiologic evaluation, including brain MRI and thorax-abdominal CT, showed partial response on CNS as well as extracranial sites, which was sustained.
DOI:
10.1177/03008916211052330
